Most Read Articles
Harriet Pugsley, MB ChB, MRCOG; Judith Moore, MRCOG, 01 Aug 2013

Most women presenting with complications in early pregnancy are assessed, diagnosed and managed at early pregnancy assessment units (EPAUs). These units aim to provide thorough assessments, access to specialist investigations (scan, human chorionic gonadotrophin [hCG]), a rapid turnaround of results, and co-ordination of further management.

07 Aug 2016
Pravastatin supplementation is associated with improved pregnancy outcomes among women with refractory obstetric antiphospholipid syndrome (APS) who developed preeclampsia (PE) or intrauterine growth restriction (IUGR) during standard antithrombotic therapy, according to a study.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.

Dietary, physical activity interventions reduce gestational weight gain

29 Jul 2017

Physical activity and dietary interventions decrease weight gain and the risk of cesarean section in pregnant women, according to a new meta-analysis.

Pooled individual participant data (IPD) from 33 studies (n=9,320) showed that gestational weight gain was significantly lower in patient who received dietary and physical activity interventions (summary mean difference, -0.70 kg; 95 percent CI, -0.92 to -0.48 kg).

Further analysis of IPD showed that diet alone (n=1,168; summary mean difference, -0.72; -1.48 to -0.91) and physical activity alone (n=2,915; summary mean difference, -0.73; -1.11 to -0.34) also reduced gestational weight gain in pregnant women.

Supplementing the above meta-analyses with data from studies that did not provide IPD, dietary and physical activity was more effective in reducing weight gain in pregnant women (n=17,530; summary mean difference, -1.1 kg; -1.46 to -0.74).

Including non-IPD studies also increased the benefit of diet alone (n=2,017; summary mean difference, -2.84; -4.77 to -0.91) on gestation weight gain. The effect of physical activity alone (n=7,355; summary mean difference, -0.72; -1.04 to -0.41) remained constant.

The risk of caesarean section was significantly reduced in patients that received the dietary and physical activity interventions (odds ratio [OR], 0.91; 0.83 to 0.99) compared with those who received routine care.

In contrast, the risks of gestational diabetes (OR, 0.89; 0.72 to 1.10), hypertensive disorders of pregnancy (OR, 0.95; 0.78 to 1.16) and preterm delivery (OR, 0.94; 0.78 to 1.13) were not significantly different.

The meta-analysis included randomized trials that examined the effects of diet and physical activity interventions on pregnancy outcomes, including gestational weight gain. Studies were retrieved from online databases including Embase, Medline and the Cochrane Database of Systemic Reviews.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Harriet Pugsley, MB ChB, MRCOG; Judith Moore, MRCOG, 01 Aug 2013

Most women presenting with complications in early pregnancy are assessed, diagnosed and managed at early pregnancy assessment units (EPAUs). These units aim to provide thorough assessments, access to specialist investigations (scan, human chorionic gonadotrophin [hCG]), a rapid turnaround of results, and co-ordination of further management.

07 Aug 2016
Pravastatin supplementation is associated with improved pregnancy outcomes among women with refractory obstetric antiphospholipid syndrome (APS) who developed preeclampsia (PE) or intrauterine growth restriction (IUGR) during standard antithrombotic therapy, according to a study.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.